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Introduction
Changes in body weight are a significant side effect of the long-term administration of some anti-epileptic drugs (AEDs). 1 A significant weight *Corresponding author. Tel.: +43-1-40400-6089; fax: +43-1-40400-3260.
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loss has been reported in connection with topiramate (TPM). 2 Data on body mass index (BMI, weight in kilograms/height in meters 2 ) parameters, including the standard deviation score (S.D.S.), of children and adolescents during TPM therapy are not available. The BMI is a standardized method of assessing body weight in all stages of life, including childhood, adolescence and adulthood. 3 The objective of this retrospective analysis was to assess E. Reiter et al. the effect of long-term topiramate therapy on BMI parameters in paediatric epilepsy patients and to examine predictors of weight loss.
Subjects
Children and adolescents aged ≤18 years, who had been commenced on TPM and who were treated for at least 12 consecutive months, were identified by searches of the study centre data-base. Subjects who fulfilled these criteria were evaluated for changes in BMI S.D.S. from baseline to the follow-up periods of 12, 24 and 36 months.
The maximum daily dose of topiramate (given in mg/kg body weight) was computed for each subject during the period of therapy initiation and at the last follow-up visit.
Methods
The BMI (kg/m 2 ) was calculated for each individual patient. Age-and sex-specific developmental changes in BMI, which are due to physiological alterations in fat mass, need to be addressed in children and adolescents. 3 Using the LMS method described by Cole, 4 standard deviation scores (S.D.S.-LMS) can be calculated by the following formula:
In this formula BMI is the individual parameter, whereas M(t), L(t) and S(t) are parameters for the age (t) and gender of the child. 3 The L curve (Box-Cox power to remove skewness), the M curve (median) and the S curve (coefficient of variation) provide information to draw any centile curve, and to convert measurements (even extreme values) into exact standard deviation scores. 4 This formula was used in the present study to calculate age-and sex-corrected S.D.S. of the BMI. These scores express the degree of deviation for any single individual BMI from the mean (=50th BMI percentile) in terms of the number of standard deviations and offer a unique opportunity to compare age-and sex-related changes in BMI over time. The significance of differences between these measures was calculated using a repeated measures t-test for paired samples if appropriate, Wilcoxon's test if values were not normally distributed, and one-way ANOVA.
Results
A total of 53 subjects (male/female ratio: 25/28) were included in the study. At the initiation of treatment the subjects ranged in age from 0.5 to 17 years (median 6.5 years; mean 7.3 years). According to Classification scheme of the ILAE, 73.6 % (n = 39) had symptomatic, 11.3% (n = 6) cryptogenic and 15.1% (n = 8) idiopathic epilepsy. Of 53 patients, 5 received TPM as monotherapy at the last visit and 48 received TPM as adjunctive therapy along with one (n = 42) or two (n = 6) concomitant AEDs. The background AEDs were as follows: valproic acid (n = 22), vigabatrin (n = 9), phenobarbital/primidone (n = 8), carbamazepine/oxcarbazepine (n = 6), lamotrigine (n = 5) and felbamate (n = 1). At the end of 12 months, 53 patients remained on TPM. TPM therapy was given to 35 patients at 24 months, and to 21 patients at 36 months. This reduction was due to either inefficacy or adverse effects.
The mean maximum daily dose of TPM was 8 mg/kg body weight (BW) (range, 1-20 mg/kg BW). 56.6% (n = 30) of the patients were seizure-free at the last visit. No subject was on a special diet or on an exercise program and no formal dietary intervention was conducted during the study.
The age of the patients, weight S.D.S. and BMI S.D.S. at baseline and follow-up (12, 24 and 36 months) are shown in Table 1 .
Statistical S.D.S. comparisons between baseline and follow-up, done by a repeated measures t-test for paired samples, revealed significant decreases for BMI S.D.S. at 12 months (P = 0.004) and 24 months (P = 0.044), but no significant decrease at 36 months. ANOVA revealed a predictor value of sex for BMI S.D.S. at 12 months (females more likely to lose weight; P = 0.037) and a predictor value of baseline BMI for BMI S.D.S. at 24 months (patients with a higher baseline BMI were more likely to lose weight; P = 0.047). BMI S.D.S. at 36 months tended to be lower for a higher baseline BMI (P = 0.064). Age, maximum dosage of TPM and number of AEDs had no predictor value. Despite significant decreases in BMI S.D.S. after 12 and 24 months of TPM treatment, no patient discontinued topiramate therapy.
Discussion
A higher BMI at the start of treatment (with no preference for female/male patients or valproic acid as concomitant AED) seems to be a predictor for weight loss during TPM treatment; patients with a higher BMI are more likely to lose weight. Accordingly, in an adult clinical trial, weight loss after 1 year of TPM treatment was most strongly correlated with a higher baseline BMI (P = 0.0007). 5 In this study, paediatric epilepsy patients revealed statistically significant decreases in the BMI S.D.S. after 12 and 24 months of TPM treatment compared to baseline BMI S.D.S., which is indicative of the sustained effect of TPM on BMI up to 2 years. Results of the present study are somewhat different from those reported by Riviello et al. 6 in which weight loss generally occurred early in therapy--although the time point was not specified--and a resumption of weight gain was reported typically after 6 months of continued TPM therapy; whereas Levison 2 reported that weight loss occurred in the first 12-18 months, after which time the patient resumes his/her normal weight gain.
Although in this study, subjects had a lower BMI S.D.S. at the 36-month follow up compared to the baseline BMI S.D.S., the difference was not statistically significant. This may have been either due to the small sample size at 36 months, or to cessation of weight loss, or even a resumption of weight gain between 24 and 36 months of TPM therapy. Despite significant decreases in BMI S.D.S. after 12 and 24 months of TPM treatment, weight loss did not necessitate drug withdrawal in any patient, which is concordant with the current literature. 2 In summary, regular calculation of BMI during TPM therapy, especially in infancy, early childhood and in mentally retarded/neurological impaired children, offers a quantitative tool to monitor changes in BMI over time. These measurements should be conducted while monitoring paediatric epilepsy patients so that changes may be detected before the onset of serious adverse consequences on the patients' physical maturation.
